Ocugen’s Gene Therapy Pipeline Dominates Earnings Call
at www.tipranks.com (Tue, 10-Mar 8:07 PM)
Ocugen: Late-Stage Retinal Pipeline and 2027–2028 Approval Catalysts Underpin Buy-Rated Risk-Reward
at www.tipranks.com (Mon, 9-Mar 6:25 AM)
Ocugen (OCGN) Receives a Buy from Maxim Group
at www.tipranks.com (Sat, 7-Mar 12:35 PM)
Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value
at www.tipranks.com (Fri, 6-Mar 1:00 AM)
